Several FDA-approved medications can treat addiction to opioids, alcohol, and nicotine, and they work by targeting different brain receptors depending on the substance involved. For opioid addiction alone, three medications have been shown to reduce overdose deaths by up to 59%. No FDA-approved medications currently exist for stimulant addictions like cocaine or methamphetamine, though clinical trials are showing early promise.
Medications for Opioid Addiction
Three medications form the backbone of opioid addiction treatment: methadone, buprenorphine, and naltrexone. All three bind to the same opioid receptors in the brain that drugs like heroin and fentanyl target, but each interacts with those receptors differently.
Methadone fully activates opioid receptors, producing mild effects that prevent withdrawal and reduce cravings without the intense high of street opioids. It’s the oldest of the three and remains the most effective at keeping people in treatment. In a multi-site clinical trial, 74% of patients on methadone completed their treatment course, compared to 46% on buprenorphine. When methadone doses were optimized, completion rates climbed to 80%. The tradeoff is that methadone requires daily visits to a licensed clinic, at least initially, which limits flexibility.
Buprenorphine partially activates opioid receptors, meaning its effects plateau at a certain dose. This ceiling effect makes it harder to misuse and safer in overdose situations. It’s commonly prescribed as a combination tablet or film (often known by the brand name Suboxone) that dissolves under the tongue. A major regulatory shift happened in 2023: the federal government eliminated the special waiver that previously limited which doctors could prescribe buprenorphine, and removed patient caps. Any practitioner with a standard DEA registration and Schedule III authority can now prescribe it, making access significantly easier. Common side effects include headache, constipation, sleep difficulties, and stomach pain. One important caution: starting buprenorphine too soon after using opioids can trigger sudden withdrawal symptoms, so timing matters.
Naltrexone takes the opposite approach. It blocks opioid receptors entirely, so if you use opioids while taking it, you won’t feel any effect. It’s available as a daily pill or a monthly injection. The injectable form delivers 380 mg and is given once every four weeks, which removes the daily decision of whether to take a pill. The catch is that you need to be completely free of opioids for 7 to 10 days before starting naltrexone, which is a significant hurdle for many people.
How These Medications Reduce Overdose Risk
Medication-assisted treatment does more than manage cravings. In a study of over 17,500 opioid overdose survivors, methadone reduced opioid-related deaths by 59% and buprenorphine reduced them by 38%, compared to no medication at all. Naltrexone did not show the same mortality benefit in that study, likely because people tend to stay on it for shorter periods. The longer someone stays on medication, the greater the protective effect.
Despite buprenorphine’s lower retention rates compared to methadone, patients who stayed on buprenorphine actually had fewer positive opioid urine tests during the first nine weeks of treatment. This suggests that both medications work well for different people, and the best choice depends on individual circumstances, lifestyle, and how much structure someone needs.
Short-Term Detox vs. Long-Term Maintenance
Medications for opioid addiction serve two distinct purposes, and confusing them is common. During detox, the goal is simply to ease withdrawal symptoms. Methadone or buprenorphine is started at a low dose and gradually tapered over days or weeks. Other medications can help with specific withdrawal symptoms: anti-nausea drugs, anti-diarrheal medications, anti-inflammatory painkillers for muscle cramps, and blood pressure medications for the flu-like symptoms that accompany opioid withdrawal.
Maintenance therapy is different. Here, the goal is long-term stability. Doses are higher, treatment continues for months or years (sometimes indefinitely), and the medication serves as a steady foundation that blocks cravings and prevents the euphoric effects of opioid use. Research consistently shows that maintenance therapy produces better long-term outcomes than short-term detox alone. Stopping medication too quickly carries real risks, including a return to use at a time when tolerance has dropped, which is when overdose is most dangerous.
Medications for Alcohol Addiction
Three medications are approved to treat alcohol use disorder, though they differ significantly in how well they work.
Naltrexone (the same drug used for opioid addiction) reduces the rewarding feeling alcohol produces in the brain. At a standard daily oral dose, it reduced the likelihood of returning to any drinking by about 7% compared to placebo across 16 clinical trials involving over 2,200 participants. A 2024 systematic review in JAMA supported oral naltrexone as a first-line treatment. It’s also available as a monthly injection.
Acamprosate helps restore the brain’s chemical balance after prolonged heavy drinking. It appears to calm the overexcited nervous system that develops during chronic alcohol use. Across 20 clinical trials with over 6,300 participants, it reduced the risk of returning to any drinking by 12% compared to placebo. The same JAMA review endorsed it alongside naltrexone as a first-line option.
Disulfiram takes a purely deterrent-based approach. It interferes with how your body processes alcohol, causing intense nausea, flushing, and headaches if you drink while taking it. The idea is that knowing you’ll feel terrible creates a strong incentive to stay sober. However, the evidence for its effectiveness is weak. Across three clinical trials, it showed no statistically significant effect on preventing a return to drinking. It only works if you take it consistently, and many people simply stop.
Medications for Nicotine Addiction
Two prescription medications help people quit smoking beyond standard nicotine replacement products like patches and gum.
Varenicline (formerly sold as Chantix) partially activates the same brain receptors that nicotine targets, producing a mild release of the reward chemical dopamine. This eases withdrawal symptoms while also blocking nicotine from producing its full pleasurable effect if you do smoke. It is the more effective of the two prescription options. In one trial, 14.4% of people taking varenicline remained smoke-free at one year, compared to 4.9% on placebo. A large meta-analysis found that varenicline was about 79% more likely to help people quit than bupropion at the 9 to 12 week mark, and that advantage held through a full year of follow-up.
Bupropion (sold as Zyban for smoking cessation) works by increasing dopamine activity in the brain, which helps offset the low mood and irritability that come with quitting. It’s less effective than varenicline. In the same trial mentioned above, bupropion’s one-year abstinence rate of 6.3% was not statistically different from placebo. Still, it works for some people, particularly those who also struggle with depression, since bupropion is also used as an antidepressant.
Stimulant Addiction: No Approved Medications Yet
There are currently no FDA-approved medications for addiction to stimulants like methamphetamine or cocaine, which represents one of the biggest gaps in addiction medicine. However, clinical research is making progress. A 2026 randomized trial found that mirtazapine, a medication originally developed for depression, reduced methamphetamine use by about two more days per month compared to placebo. Participants did experience more drowsiness (47% vs. 33%) and weight gain (10% vs. 3%), but no unexpected safety issues emerged. Other approaches being tested include high-dose prescription stimulants and long-acting opioid-blocking medications, though none are ready for routine clinical use.
For now, treatment for stimulant addiction relies primarily on behavioral therapies, including structured reward-based programs where patients earn incentives for staying drug-free. These approaches have solid evidence behind them, even without a medication component.